Tango Therapeutics, Inc. (TNGX)

Market Cap	421.08M
Revenue (ttm)	43.38M
Net Income (ttm)	-123.40M
Shares Out	107.42M
EPS (ttm)	-1.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,268,481
Open	3.590
Previous Close	3.630
Day's Range	3.430 - 3.950
52-Week Range	2.700 - 13.010
Beta	0.88
Analysts	Strong Buy
Price Target	13.14 (+235.2%)
Earnings Date	Nov 6, 2024

About TNGX

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 140
• Stock Exchange: NASDAQ
• Ticker Symbol: TNGX
• Website: https://www.tangotx.com

Financial Performance

In 2023, Tango Therapeutics's revenue was $36.53 million, an increase of 46.93% compared to the previous year's $24.86 million. Losses were -$101.74 million, -5.95% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price forecast is $13.14, which is an increase of 235.20% from the latest price.

Price Target

$13.14

(235.20% upside)

Analyst Consensus: Strong Buy